Byetta/Januvia Pancreatic Cancer

Diabetes experts support Byetta, Januvia critic

A number of the world’s top diabetes experts agree with Dr. Peter C. Butler, an internationally renowned physician who raised alarms about the diabetes drugs Januvia and Byetta.

A story on MedPage Today quotes Andrew Boulton, MD, president of the European Association for the Study of Diabetes (EASD), as saying that he has the “highest respect for Peter Butler as a colleague, clinician and scientist.”

The New York Times recently ran a profile ...

continue reading...

Study says blood test promising for pancreatic cancer

Japanese researchers are optimistic about the results of a study suggesting that a new blood test designed to detect pancreatic cancer early may improve patients’ odds for survival.

A HealthDay News story says the improved odds are relatively small. But given the nature of pancreatic cancer, any potential improvement is good news.

The five-year survival rate for pancreatic cancer is currently less than 5 percent, in large part because it has usually spread ...

continue reading...

FDA panel votes to reduce Avandia restrictions

A U.S. Food and Drug Administration panel has recommended allowing the diabetes drug Avandia to remain on the market with relaxed restrictions on its use, according to NBC News.

The story says Avandia was once the world’s top-selling diabetes drug. But in 2007, an analysis of other studies suggested that it raised the risk of heart attack by 43 percent. European regulators removed it from the market in 2010 and the FDA ...

continue reading...

Report: Byetta, Januvia, makers downplayed risk of pancreatic cancer

The prestigious medical journal BMJ has published a damning investigative article on a crop of new diabetes drugs called “incretin therapies,” which include Byetta and Januvia.

The article mentions a number of studies that have been published in recent years, indicating a potential link between these drugs and a potentially deadly inflammation of the pancreas called pancreatitis, as well as pancreatic cancer. Byetta has also been linked to thyroid cancer.

But the BMJ ...

continue reading...

FDA diabetes drug review is controversial

According to U.S. News and World Report, the Food and Drug Administration’s decision to reevaluate the diabetes drug Avandia is proving controversial, with some detractors accusing the agency of unnecessarily wasting taxpayer resources.

Avandia was once a top-selling medication for its manufacturer, GlaxoSmithKline. But a 2007 study concluded that it raised the risk of heart attack by more than 40 percent. As a result, the FDA imposed restrictions on Avandia in 2011, ...

continue reading...

Diabetes drugs Byetta, Januvia generating lawsuits

A New York Times story about the link between certain diabetes drugs and pancreatic cancer, says that more than 100 lawsuits have been filed. According to the report, more than 575 plaintiffs around the country are claiming injury from Byetta, and more than 40 claim Januvia caused pancreatic cancer.

Meanwhile, Dr. Peter C. Butler, an internationally renowned diabetes expert who first sounded health warnings about the link is standing up to fierce ...

continue reading...
Page 4 of 13 «...23456...»